# Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome

> **NCT00542269** · PHASE4 · TERMINATED · sponsor: **Novartis** · enrollment: 178 (actual)

## Conditions studied

- Hypertension With Metabolic Syndrome

## Interventions

- **DRUG:** Amlodipine
- **DRUG:** Aliskiren
- **DRUG:** Ramipril

## Key facts

- **NCT ID:** NCT00542269
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 178 (ACTUAL)
- **Why stopped:** Early termination of the study due to slow recruitment.
- **Last updated:** 2011-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542269, "Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00542269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*